Omeros reports Q3 2026 results, CHMP negative opinion on narsoplimab in Europe
YARTEMLEA U.S. sales rose as the company outlined 2026-2027 trial starts for OMS1029, OMS527, and OncotoX-AML, while Novo's zaltenibart Phase 3 stays on track.
SEC filing
27 stories
YARTEMLEA U.S. sales rose as the company outlined 2026-2027 trial starts for OMS1029, OMS527, and OncotoX-AML, while Novo's zaltenibart Phase 3 stays on track.
SEC filing
Insight Molecular Diagnostics said the FDA paused its review clock after requesting more data on GraftAssureDx, with a response due before January 21, 2027.
SEC filing
The Nasdaq Capital Market company filed a preliminary prospectus supplement for a stock and pre-funded warrant offering while its De Novo request for a transplant rejection test remains under FDA review.
SEC filing
The company said it completed PMDA pre-filing requirements in Japan for CardiAMP and expects to submit a Helix De Novo application to FDA in early 2027.
SEC filing
Phase 1 data for hypoparathyroidism candidate SEP-479 are expected in Q1 2027, the same quarter Septerna plans to start a Phase 1 trial of new candidate SEP-204.
SEC filing
The company said topline interim results from its pivotal FORTIFI-HN01 study are expected in mid-2027, while cash on hand is projected to fund operations into the first half of 2029.
SEC filing (10)
Korro reported dosing of healthy volunteers in its ANCHOR trial and preclinical data for KRRO-111, while disclosing Novo Nordisk's move to terminate their collaboration agreement effective February 1, 2027.
SEC filing
Ginkgo said third-quarter revenue fell 6% to $28 million while losses narrowed, and disclosed an autonomous lab sale to Novo along with new government contracts.
SEC filing (2)
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
The board's compensation committee awarded Gregory Demopulos an option for up to 500,000 shares that vests only if Omeros stock hits price targets from $25 to $40.
SEC filing
The agency cleared a priority-reviewed supplemental biologics license application for the insulin icodec injection on October 23, 2026.
Drugs@FDA
The appointment to Evotec's Management Board takes effect November 1, 2026, bringing in a 25-year industry veteran to oversee scientific strategy.
SEC filing
The company reported on October 1, 2026 that it filed an updated De Novo pre-submission with FDA's device center for its Helix catheter.
SEC filing